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Abstract
Background: At present, women with threatened preterm labor before 32 weeks of gestation
are, after transfer to a perinatal center, treated with tocolytics and corticosteroids. Many of these
women are treated unnecessarily. Fibronectin is an accurate predictor for the occurrence of
preterm birth among women with threatened preterm labor. We will assess whether triage of
these women with fibronectin testing, cervical length or their combination is cost-effective.
Methods/Design: We will investigate a prospective cohort of women referred to a perinatal
centre for spontaneous threatened preterm labor between 24 and 34 weeks with intact
membranes. All women will be tested for fibronectin and cervical length. Women with a cervical
length <10 mm and women with a cervical length between 10-30 mm in combination with a positive
fibronectin test will be treated with tocolytics according to local protocol. Women with a cervical
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between treatment with nifedipine (intervention) and placebo (control) for 48 hours. Women with
a cervical length > 30 mm will be managed according to local protocol. Corticosteroids may be
given to all women at the discretion of the attending physician. Primary outcome measure will be
delivery within 7 days. Secondary outcome measures will be neonatal morbidity and mortality,
complications of tocolytics, costs and health related quality of life. The analysis will be according to
the intention to treat principle. We anticipate the probability on preterm birth within 7 days in the
group of women with a negative fibronectine test to be 5%. Two groups of 110 women will be
needed to assure that in case of non-inferiority the difference in the proportion of preterm
deliveries < 7 days will be within a prespecified boundary of 7.5% (one sided test, β 0.2, α 0.05).
Data obtained from women with a positive and negative fibronectin tests in both the cohort study
and the trial will be integrated in a cost-effectiveness analysis that will assess economic
consequences of the use of fibronectin.
Discussion: This study will provide evidence for the use of fibronectin testing as safe and cost-
effective method in a triage for threatened preterm labor.
Trial registration: Nederlands Trial Register (NTR) number 1857, http://www.trialregister.nl.
Background
Preterm birth is the most frequent cause of perinatal mor-
tality and severe perinatal morbidity in the Western world
[1]. Preterm birth can be preceded by rupture of the mem-
branes and/or by uterine contractions leading to cervical
effacement and dilation. Current treatment of women
with threatened preterm labor is tocolysis to diminish
contractions and the administration of corticosteroids to
enhance fetal lung development [2]. In the Netherlands,
7.9% of all deliveries are preterm, and 1.6% of all
neonates are born before 32 weeks of gestation [3].
Women at risk for preterm birth prior to 32 weeks are
transferred to a perinatal centre [4].
Discriminating those women who will deliver preterm is
difficult: about half of the women treated with tocolytics
and/or corticosteroids do not deliver within a short time
after the occurrence of symptoms. As tocolytics and corti-
costeroids can cause severe side-effects in both mother
and child [5-8], concerns have been expressed about over-
treatment. If we are able to identify women that eventu-
ally do not deliver preterm and thus do not benefit from
referral and treatment, we could prevent them from being
exposed to the potential side effects of tocolytics and cor-
ticosteroids. In addition, management costs could be
reduced by preventing unnecessary transport of pregnant
women to perinatal centers and the associated higher
treatment costs.
Fetal fibronectin is an internationally accepted predictor
of preterm birth [9]. Fetal fibronectin is a glycoprotein
found in amniotic fluid, placental tissue, and the extracel-
lular substance of the decidua next to the placental inter-
villous space. It is thought to be released through
mechanical or inflammatory mediated damage to the
membranes or placenta before birth [10]. Swabs can be
taken from the ectocervix or posterior vaginal fornix, and
an enzyme linked immunosorbent assay (ELISA) contain-
ing FDC6 monoclonal antibody can be used to detect fetal
fibronectin [11]. The results may indicate the likelihood
of spontaneous preterm birth [12]. In clinical use, how-
ever, factors such as contamination of the sample with
maternal blood, sampling within 24 hours after inter-
course, and preeclampsia may reduce the accuracy of the
test and give false positive results [13-15].
The predictive capacity of fibronectin has been the topic of
previous studies. Honest and co-workers published in
2002 a systematic review on the predictive capacity of
fibronectin for preterm delivery [16]. They identified 40
studies reporting on symptomatic women. The summary
likelihood ratio for a positive result was 5.4 (95% CI 4.4
to 6.7) for predicting birth within 7 to 10 days of testing,
with a corresponding likelihood ratio for a negative result
of 0.25 (95% CI 0.20 to 0.31). Therefore fibronectin test-
ing might be able to reduce unnecessary treatment and
subsequent costs. On the other hand, introducing
fibronectin tests has not yet proven to reduce health care
costs if the subsequent management is subject to physi-
cians preferences [17-21]. In addition, high false positive
rates may increase health care costs in the management of
low risk women.
For cervical length measurement, the situation is different.
This test is shown to predict preterm delivery in asympto-
matic women at 20 weeks [22]. However, the accuracy of
the test is only marginally evaluated in women with symp-
toms of preterm labor at a later gestational age [23].
Gomez et al. evaluated the predictive accuracy of a combi-
nation of fetal fibronectin measurement and cervicalPage 2 of 6
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women had cervical lengths below 15 mm, and one third
of these women delivered within 48 hours. Among those
with a cervical length between 15 mm and 30 mm (36%
of the population), 25% had a positive fibronectin test,
and 15% of this group delivered within 48 hours. Of the
remaining 75% of the women, less than 5% delivered
within 7 days. These results are comparable with our pilot
study of Wilms et al. Amongst 19 women with a cervical
length between 10-30 mm and a negative fibronectin test,
only 1 woman delivered within 7 days[25].
At present, fibronectin testing is not routinely used in The
Netherlands. To assess the risk for threatened preterm
labor, only cervical length is routinely measured[2]. This
measurement is frequently used as an argument to trans-
fer and treat women for threatened preterm labor, even if
clinical symptoms are mild. Identifying women that are at
high risk for preterm delivery could benefit from adding
fibronectin testing. Therefore we will evaluate if adding
fibronectin testing to cervical length measurement is a safe
and cost-effective strategy as a triage for women with
threatened preterm labor.
Methods/Design
Aims
We will evaluate a risk assessment with fibronectin testing
for women with clinical signs of threatened preterm labor.
We will assess whether triage of these women with
fibronectin testing, cervical length measurements or a
combination is cost-effective. The results of this study can
be used to support a policy of expectant management
without immediate referral to a neonatal centre and with-
out tocolysis in women with a low risk for preterm birth.
Participants/eligibility criteria
All women between 24 and 34 weeks of gestational age
with primary complaints associated with preterm labor
and intact membranes will be eligible for inclusion in the
study. Women with vaginal bleeding, a cerclage, cervical
dilatation of more than 3 cm or previous treatment for
threatened preterm labor in the current pregnancy are
excluded. Other exclusion criteria are hypertension, con-
tra indications for nifedipine and fetal distress or maternal
conditions that may lead to pregnancy termination within
7 days. The study will be limited to women admitted to a
perinatal centre with neonatal intensive care facilities.
Procedures, recruitment, randomisation and collection of 
baseline data
Women meeting the eligibility criteria will be informed
and invited to participate in the study and asked for writ-
ten informed consent. At study entry baseline demograph-
ics, obstetric and medical history will be recorded. Before
cervical length measurement, women will be tested for
fibronectin. Therefore a sample of cervicovaginal secre-
tion will be taken by rotating a swab in the posterior vag-
inal fornix for 10 seconds. Analysis will be performed
using the FullTerm TLiIQ system of Hologic [26].
Women with a cervical length below 10 mm and women
with a cervical length between 10-30 mm in combination
with a positive fibronectin test will be treated with tocoly-
sis. These women are considered to be at high risk for pre-
term delivery. Women with a cervical length above 30 mm
will be treated according to the discretion of the physi-
cian. Women with a cervical length between 10-30 mm
and a negative fibronectin test are considered to be at low
risk, they will enter a double blind trial in which they will
be randomised by a central web-based system between
tocolytics or placebo (1:1). Details of delivery and mater-
nal assessments during pregnancy of all women are
recorded in case record forms (CRF) that are accessible
through a closed part of a central website. All data will be
collected, coded and processed with adequate precautions
to ensure patient confidentiality.
Interventions
All high risk women will receive tocolytics according to
local protocol. Fibronectin negative women with a cervi-
cal length between 10-30 mm will be randomly allocated
to tocolytics or placebo (figure 1). Active treatment will be
performed with the calcium channel blocking agent nifed-
ipine with a total daily dose between 80 and 120 milli-
grams for 48 hours. Active drug and placebo will be
administered orally at the same volume and rate. Corti-
costeroids will be administered at the discretion of the
attending physician.
Progression of labor will be monitored every 12 hours by
means of clinical observation and/or vaginal examina-
tions for 48 hours. If labor seems inevitable in that period,
study medication can be stopped and another tocolytic
(excluding nifedipine) may be administered.
Follow up of women and infants
Details of admission of newborns to the neonatal inten-
sive care unit and neonatal complications will be
recorded. Long term follow up is not part of this study.
Outcome measures
The primary outcome measure is number of days to deliv-
ery truncated at 7 days after study entry. Secondary end-
points are neonatal mortality, neonatal morbidity,
maternal morbidity (side effects of nifedipine), costs and
health related quality of life.Page 3 of 6
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Sample size
The randomised trial in our study will be a non-inferiority
effectiveness trial. Based on our pilot study [25], we antic-
ipate the probability on preterm birth within 7 days in the
group of women with a negative fibronectine test and a
cervical length 10-30 mm to be 5%. We need 220
fibronectin negative women in the cohort (110 per arm)
to assure with 80% power that in case of non-inferiority
the upper limit of the 95% one-sided CI for the difference
in the proportion of preterm deliveries < 7 days will be
within a prespecified boundary of 7.5%. According to our
pilot we will need a cohort of approximately 660 women
[25].
Data analysis
The results of the randomised trial will be analyzed
according to the intention to treat principle. We will ana-
lyze costs and effects of a strategy based on fibronectin
measurement and cervical length, in which only fibronec-
tin positive women will be transferred to a perinatal center
and/or and treated. Costs and effects of this strategy will
be compared to a strategy in which these women will be
transferred and treated merely based on a clinical diagno-
sis by e.g. vaginal examination and/or cervical length
measurement.
Interim analysis
After 100 fibronectin negative, low risk women have
entered the randomised trial, an interim analysis will be
performed by an external independent safety committee.
Interim analysis will be performed on the primary out-
come only, e.g. percentage of preterm deliveries within 7
days after fibronectin testing. If there is a significant differ-
ence between the groups treated with tocolytics and pla-
cebo, the independent safety committee will decide about
further unblinding of the interim results and (dis)contin-
uation of the trial.
Economic evaluation
The aim of the economic evaluation is to assess whether
fibronectin testing as a triage for women with threatened
preterm labor is cost-effective. For the cost analysis we dis-
tinguish cost within the antenatal period, during delivery
and childbirth and within the postnatal period. As the
study will be performed from a societal perspective, three
cost categories will be included: direct medical costs,
direct non-medical costs and indirect costs. Volumes of
health care resource use during the index admission are
measured prospectively alongside the clinical study in all
participating centers as part of the CRF. Questionnaires
addressing health related quality of life will be adminis-
tered in a random subsample.
If the randomised trial indicates that a particular sub-
group of women does not benefit from treatment with
tocolytics, the economic analysis will be a cost-minimiza-
tion analysis. If tocolysis and transferring low risk women
would not be necessary, the costs of risk assessment
(int.al. fibronectin testing) of the whole cohort of women
Flow chart APOSTEL-I study, an overview of which patients in the APOSTEL-I cohort will be randomized based on their cervi-cal length and fibronectin statusigure 1
Flow chart APOSTEL-I study, an overview of which patients in the APOSTEL-I cohort will be randomized 
based on their cervical length and fibronectin status.
GA 24-34 weeks
Sympt. preterm labor
Intact membranes
Cervical length
and 
Fibronectin (Fn)
Cervix 10-30 mm
and
Fibronectin neg.
Cervix 10-30 mm
and
Fibronectin pos.
Placebo
Cervix > 30 mm
(Fn pos. or neg.)
Cervix < 10 mm
(Fn pos. or neg.) Cohort (tocolysis)
Cohort (tocolysis)
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(local protocol)
Tocolysis with 
nifedipine
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more, scenario analyses for relevant subgroups will be
performed. Before analyzing the data from the study, a
detailed cost analysis model will be developed.
The trial results will be incorporated in a diagnostic model
to compare a risk assessment strategy for women with
threatening preterm labor within current practice, which
does not include additional risk assessment with fibronec-
tin.
The study design will enable us to compare the costs and
effects of the following strategies:
I. transfer and treat all women with threatening preterm
labor
II. transfer and treat women based on the results of
fibronectin measurement. As we also measure cervical
length, we can also evaluate the following strategies:
III. transfer and treat women based on the results of cervi-
cal length measurement
IV. transfer and treat women based on a combination of
cervical length measurement and fibronectin measure-
ment
V. sequential combinations, for example first cervical
length measurement, and fibronectin measurement in a
part of that women, or vice versa.
In our cohort, we will obtain data on the moment of deliv-
ery in women treated with tocolytics and not treated with
tocolytics. In addition to our cohort data, we will obtain
data from medical literature on the occurrence of neonatal
mortality and morbidity in relation to duration of preg-
nancy, both with and without treatment of corticoster-
oids. We will use this to calculate the expected neonatal
mortality and morbidity for each of the five strategies
mentioned above.
Ethical consideration
This study has been approved by the ethics committee of
the Academic Medical Centre Amsterdam (ref.no MEC
08/363).
Discussion
In women with clinical signs of threatened preterm labor,
fibronectin can discriminate between those at low risk
and high risk for immediate preterm delivery. Since treat-
ment of low risk women might be unnecessary, testing for
fibronectin is thought to be a cost effective strategy. It may
protect mother and fetus from possible side effects of toc-
olytics and corticosteroids, lessen burden of perinatal
centers and decrease stress and anxiety for the families. So
far, no randomised trial has shown beneficial effects of
fibronectin testing for women presenting with threatened
preterm labor, despite its high negative predictive value.
Although the use of fibronectin tests for these women is
already implemented in some clinics and even incorpo-
rated into guidelines [27], neither its safety as a triage
instrument, nor its cost effectiveness has been established.
We decided to use a fixed protocol to translate the test
results into a management strategy with nifedipine, to out
rule the influence of individual physicians. Nifedipine has
not yet been tested against placebo as a tocolytic drug,
though both the Cochrane Collaboration [28] and the
Dutch Society of Obstetrics and Gynaecology [2] recom-
mend calcium antagonists as first choice. It is unlikely that
using another tocolytic drug would lead to different out-
comes of this trial, since fibronectin negative women have
a low a priori probability of delivering within 7 days after
the test. So even though we randomize on therapy level,
this trial will evaluate fibronectin testing and cervical
length measurement for women with threatened preterm
labor.
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